RBC Capital Markets downgraded SAGE Therapeutics to Sell due to concerns over drug trial outcomes, reducing price target to $4. Analysts doubt the success of dalzanemdor in treating Huntington's and Alzheimer's diseases. Sage's profitability hinges on drug success.